TY  - GEN
AU  - Raja,Srikumar M
AU  - Clubb,Robert J
AU  - Ortega-Cava,Cesar
AU  - Williams,Stetson H
AU  - Bailey,Tameka A
AU  - Duan,Lei
AU  - Zhao,Xiangshan
AU  - Reddi,Alagarasamy L
AU  - Nyong,Abijah M
AU  - Natarajan,Amarnath
AU  - Band,Vimla
AU  - Band,Hamid
TI  - Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers
SN  - 1555-8576
PY  - 2011///0426
KW  - Animals
KW  - Antibodies, Monoclonal
KW  - pharmacology
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Cell Line, Tumor
KW  - Cell Survival
KW  - drug effects
KW  - Dose-Response Relationship, Drug
KW  - Drug Evaluation, Preclinical
KW  - Drug Synergism
KW  - Female
KW  - HSP90 Heat-Shock Proteins
KW  - antagonists & inhibitors
KW  - Humans
KW  - Inhibitory Concentration 50
KW  - Lapatinib
KW  - Mice
KW  - Mice, SCID
KW  - Pentacyclic Triterpenes
KW  - Quinazolines
KW  - Receptor, ErbB-2
KW  - Signal Transduction
KW  - Trastuzumab
KW  - Triterpenes
KW  - administration & dosage
KW  - Tumor Burden
KW  - Xenograft Model Antitumor Assays
KW  - methods
N1  - Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S
UR  - https://doi.org/10.4161/cbt.11.2.13959
ER  -